MAIN CONTENT
Beyond the AI trade: a broader investment conversation
Artificial intelligence has dominated the market narrative, as investors financed chips, software, data centres and the infrastructure required for increasingly powerful computing. Such enthusiasm can accelerate innovation, but high expectations also place enormous pressure on future earnings. When capital expenditure runs ahead of predictable returns, the question changes from how quickly a sector can grow to which companies can make that growth profitable. Citigroup's outlook does not imply the AI opportunity has vanished; rather, it suggests that attention and capital could become less concentrated.
Yuan noted that biotech and biomedical fundraising has been comparatively subdued this year after stronger activity in the preceding year. A quieter market does not necessarily signal the end of investor interest. Drug developers often time their listings around clinical readouts, financing needs and valuation conditions. If global funds increasingly reward demonstrable expertise instead of sweeping narratives, companies that previously waited on the sidelines could receive a fresh hearing.
Three promising sectors, three different risks
Biotechnology offers potential breakthroughs in therapies, diagnostics and research platforms, but faces regulatory approval risk and lengthy development cycles. Advanced manufacturing can provide exposure to robotics, precision equipment, materials and industrial efficiency; buyers nevertheless need to distinguish genuine technical leadership from ambitious marketing.














